TNFRSF11B and Paget disease: In addition, in a clinical study involving a group of patients with Paget’s disease, intravenous treatment with pamidronate caused an increase in OPG levels that become statistically significant after 3 and 6 months, and authors suggested that the positive effects of BPs in this disease may be because of either direct or indirect decrease in RANKL-induced bone resorption through increased OPG 61.